Location History:
- Falicon, FR (1994 - 1997)
- Nice, FR (1997 - 1998)
Company Filing History:
Years Active: 1994-1998
Title: Pierre Vierling: Innovator in Phosphorus Compounds
Introduction
Pierre Vierling, an accomplished inventor based in Falicon, France, has made significant contributions to the field of chemistry through his innovative work on phosphorus compounds. With a total of five patents to his name, Vierling's research focuses on the preparation and application of perfluoroalkylated amphiphilic phosphorus compounds, which have diverse industrial applications.
Latest Patents
Vierling's latest patents showcase his expertise and creativity in developing novel chemical compounds. His notable patents include:
1. Perfluoroalkylated amphiphilic phosphorus compounds: preparation.
2. Perfluoroalkylated amphiphilic phosphorus compounds, corresponding to the formulae: ##STR1## wherein V is O or S.
3. Perfluorinated amphiphilic phosphorous compounds: liposomal compositions.
4. Perfluoroalkylated amphiphilic phosphorus compounds, corresponding to the formulae: ##STR1## wherein V is O or S.
Career Highlights
Throughout his career, Pierre Vierling has worked with well-established companies in the pharmaceutical and technology sectors. His experience at Alliance Pharmaceutical Corporation and Application et Transferts de Technologies Avancées has been instrumental in advancing his research on phosphorus compounds, contributing to various advancements in the field.
Collaborations
Vierling's success can also be attributed to his collaborations with esteemed colleagues in his field. Notable coworkers include Jean G. Riess and Jacques Greiner, with whom he has collaborated on various projects focused on innovative chemical solutions.
Conclusion
Pierre Vierling's contributions to the development of perfluoroalkylated amphiphilic phosphorus compounds underscore his role as a prominent inventor in the field of chemistry. His extensive patent portfolio reflects his commitment to innovation and excellence, solidifying his legacy in the scientific community.